Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 767Lung Neoplasms 340Ovarian Neoplasms 318Breast Neoplasms 277Fallopian Tube Neoplasms 158Triple Negative Breast Neoplasms 144Small Cell Lung Carcinoma 142Neoplasms 134Squamous Cell Carcinoma of Head and Neck 122Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 77Esophageal Neoplasms 71Uterine Cervical Neoplasms 70Adenocarcinoma of Lung 69Neuroblastoma 55Central Nervous System Neoplasms 52Carcinoma 50Lymphoma, Large B-Cell, Diffuse 49Brain Neoplasms 48Recurrence 47Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Lymphoma, Non-Hodgkin 31

Interventions

pembrolizumab 7lenvatinib 3apatinib 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Carboplatin 3gallium 68 PSMA-11 2Specimen Handling 2Protons 2Nivolumab 2Epirubicin 2Cisplatin 2Axitinib 24-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2tislelizumab 1regorafenib 1enfortumab vedotin 1cabozantinib 1avelumab 1anlotinib 1amivantamab 1abemaciclib 1Tretinoin 1Trastuzumab 1Tablets 1Sunitinib 1Standard of Care 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Adenoid Cystic × Carboplatin × Clear all
NCT03781986 2026-03-03

APG-115 in Salivary Gland Cancer Trial

University of Michigan Rogel Cancer Center

Phase 1/2 Active not recruiting
41 enrolled
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT05010629 2025-05-31

9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
35 enrolled
Head & Neck

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

NCT04832438 2022-02-22

9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma

Actuate Therapeutics Inc.

Phase 2 Withdrawn
Head & Neck

Carcinoma, Adenoid Cystic, Neoplasm Metastasis, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡